4D Molecular Therapeutics, Inc. (FDMT)
| Previous close | 26.76 |
| Open | 26.79 |
| Bid | 26.77 x 200 |
| Ask | 26.95 x 100 |
| Day's range | 26.26 - 27.09 |
| 52-week range | 9.44 - 36.25 |
| Volume | |
| Avg. volume | 781,172 |
| Market cap | 1.373B |
| Beta (5Y monthly) | 2.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.58 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 52.20 |
GlobeNewswire4DMT to Participate in Upcoming Investor Conference
EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at an upcoming investor conference in May. Members of the management team will also be available for one-on-one meetings. Bank of America Health Care Conference 2024 Presen
Zacks4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
4D Molecular Therapeutics (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
4DMT Announces Presentations at ARVO 2024 Annual Meeting
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced presentations at the 2
